CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Tesevatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02844439
NCT02844439Phase 2Completed
CompareCT.gov

A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Kadmon Corporation, LLC·interventional·Posted Jul 26, 2016·Updated Sep 22, 2021

In Brief

A Phase 2 clinical trial evaluating Tesevatinib for Glioblastoma and 2 related conditions. Completed, enrolled 40 participants across 11 sites.

Detailed Summary

This is a multicenter, Phase 2 study to assess the activity of tesevatinib in patients with recurrent glioblastoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma, Recurrent Glioblastoma, Brain Tumor
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 26, 2016
Enrollment StartJun 1, 2016
Primary CompletionApr 30, 2020
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 9.9 years ago

Interventions

Tesevatinibdrug